RECRUITING

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Talk to us

Conditions

Relapsed or Refractory Multiple MyelomaBMS-986348CC-92480CarfilzomibDexamethasoneMultiple MyelomaMezigdomide

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Official Title

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

Quick Facts

Study Start:2023-01-10
Study Completion:2029-07-25
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05552976

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site #.
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

USA Mitchell Cancer Institute
Mobile, Alabama, 36604
United States
TOI Clinical Research
Cerritos, California, 90703
United States
Kaiser Permanente - Irvine
Irvine, California, 92618
United States
Los Angeles Hematology Oncology Medical Group
Los Angeles, California, 90017
United States
Local Institution - 0344
Santa Rosa, California, 95403
United States
Stockton Hematology Oncology Group
Stockton, California, 95204
United States
Local Institution - 0279
Newark, Delaware, 19713
United States
Local Institution - 0341
Fort Myers, Florida, 33901
United States
Local Institution - 0342
Saint Petersburg, Florida, 33705
United States
Local Institution - 0340
West Palm Beach, Florida, 33401
United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322
United States
Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
United States
Anne Arundel Medical Center
Annapolis, Maryland, 21401
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Local Institution - 0346
Minneapolis, Minnesota, 55404
United States
Regional Cancer Care Associates
Little Silver, New Jersey, 07739
United States
Montefiore Medical Center
Bronx, New York, 10467
United States
University of North Carolina Medical Center
Chapel Hill, North Carolina, 27599
United States
Local Institution - 0322
Cleveland, Ohio, 44106
United States
Riverside Methodist Hospital
Columbus, Ohio, 43214
United States
Local Institution - 0321
Providence, Rhode Island, 02903
United States
Charleston Oncology, P.A.
Charleston, South Carolina, 29414
United States
Local Institution - 0338
Greer, South Carolina, 29650
United States
Local Institution - 0323
Nashville, Tennessee, 37203
United States
Local Institution - 0337
Fort Worth, Texas, 76104
United States
Kelsey-Seybold Clinic
Houston, Texas, 77025
United States
Houston Methodist Hospital
Houston, Texas, 77030
United States
Baylor Scott & White Medical Center - Temple
Temple, Texas, 76508
United States
Local Institution - 0345
Norfolk, Virginia, 23502
United States
Local Institution - 0343
Roanoke, Virginia, 24014
United States
Northwest Medical Specialties PLLC
Tacoma, Washington, 98405
United States
Local Institution - 0347
Vancouver, Washington, 98684
United States
WVU Cancer Institute
Morgantown, West Virginia, 26506
United States
Local Institution - 0336
Marshfield, Wisconsin, 54449
United States

Collaborators and Investigators

Sponsor: Bristol-Myers Squibb

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-10
Study Completion Date2029-07-25

Study Record Updates

Study Start Date2023-01-10
Study Completion Date2029-07-25

Terms related to this study

Keywords Provided by Researchers

  • BMS-986348
  • CC-92480
  • Carfilzomib
  • Dexamethasone
  • Multiple Myeloma
  • Mezigdomide

Additional Relevant MeSH Terms

  • Relapsed or Refractory Multiple Myeloma